ALAMEDA, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the 2016 Aegis Growth Conference on Thursday, September 22, 2016 at 5:30 p.m. ET/ 2:30 p.m. PT. The conference will be held at the Encore at Wynn Hotel in Las Vegas.
A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the investor relations section of the Company’s website.
About OncoCyte Corporation
OncoCyte is primarily focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for detecting lung, bladder and breast cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein markers that differentially express in specific types of cancer.